AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31167875
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel (reference) after PCI
Trial: 31167875
Drug: Aspirin (reference)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (reference) after CABG
Trial: 31167875
Drug: DAPT plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT plus an anticoagulant (Triple Therapy)
Trial: 22075192
Drug: Contrast injection
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast injection (ConI)
Trial: 9661644
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metformin, x 3 daily for 2 months
Trial: 9661644
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg metformin, x 3 daily for 4-6 months (in 12 women)
Trial: 28235705
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge administered immediately prior to the stressor
Trial: 28235705
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge administered 10 minutes prior to the stressor
Trial: 28235705
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge administered prior to the stressor
Trial: 28235705
Drug: Nicotine lozenge
RxNorm normalized name: nicotine Lozenge Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine lozenge administered after the stressor
Trial: 22930256
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy (rituximab and azathioprine)
Trial: 16547531
Drug: Beta-blockers with
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-blockers with vasodilatory properties
Trial: 12867587
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg methylprednisolone acetate (MPA)
Trial: 10619792
Drug: High-dose CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CPB chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) and peripheral blood progenitor cell support (PBPCS)
Trial: 10619792
Drug: Standard-dose CPB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose CPB chemotherapy (SDC)
Trial: 10619792
Drug: Induction CAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction CAF chemotherapy
Trial: 10619792
Drug: Prednisone treatment
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone treatment for DPTS
Trial: 1629142
Drug: Enalapril (5-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5-20 mg daily, mean dose 7.2 mg)
Trial: 6091248
Drug: ACTH 1‐17
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACTH 1‐17 (100 micrograms i.m. daily for 15 days during 6 consecutive months)
Trial: 6091248
Drug: Saline (placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (placebo injections)
Trial: 31200638
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion (1 mg bolus over 30 min followed by 2 μg/kg/h continuous infusion)
Trial: 31200638
Drug: Terlipressin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terlipressin infusion and Control (normal saline)
Trial: 20808113
Drug: Hormonal replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormonal replacement therapy, Mediterranean diet, caffeine and alcohol intake as protective factors
Trial: 19331578
Drug: 10(6)-cfu CTV-05
RxNorm normalized name: Lactobacillus crispatus (CTV-05)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10(6)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Trial: 19331578
Drug: 10(8)-cfu CTV-05
RxNorm normalized name: Lactobacillus crispatus (CTV-05)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10(8)-cfu CTV-05 capsules inserted intravaginally twice daily for 3 days
Trial: 17342295
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg Depo-Medrol
Trial: 17342295
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg Depo-Medrol
Trial: 11672948
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 g/kg bodyweight)
Trial: 9626212
Drug: CODE (cisplatin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CODE (cisplatin, vincristine, doxorubicin, etoposide + G-CSF)
Trial: 28665340
Drug: Therapy dog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy dog (TD) exposure (n = 31)
Trial: 23243082
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg elemental iron once weekly (group A)
Trial: 23243082
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg elemental iron once daily (group B)
Trial: 23243082
Drug: 0.5 ml
RxNorm normalized name: ethanol 0.5 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml of a natural color additive (control group C)
Trial: 17960589
Drug: Individual or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individual or no therapy (Control)
Trial: 15598063
Drug: Community-based pharmaceutical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community-based pharmaceutical care for the elderly
Trial: 10866043
Drug: Intravenous and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and/or subcutaneous insulin in 29 patients with newly diagnosed type 1 diabetes
Trial: 10866043
Drug: Subcutaneous insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous insulin prophylaxis in 14 islet cell antibody-positive relatives
Trial: 10866043
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) plus subcutaneous insulin in 10 newly diagnosed patients
Trial: 9349929
Drug: Turbuhaler (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Turbuhaler (1.2 mg salbutamol, 12 x 100 micrograms)
Trial: 9349929
Drug: Diskus (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diskus (1.2 mg salbutamol, 6 x 200 micrograms)
Trial: 27352955
Drug: High adherence
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High adherence (≥80% medication adherence)
Trial: 27352955
Drug: Low adherence
RxNorm normalized name: dressing,low adherence and wound contact materials
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low adherence (<80% medication adherence)
Trial: 22976260
Drug: Achillea millefolium
RxNorm normalized name: ACHILLEA MILLEFOLIUM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea millefolium (1.5 g powdered flower, 3 days a week for 2 months)
Trial: 12394379
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (10 colony-forming units daily)
Trial: 1960663
Drug: Formaldehyde-tyrothricin solution
RxNorm normalized name: Tyrothricin
DrugBank: Tyrothricin (DB13503)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formaldehyde-tyrothricin solution placed in periodontal pockets
Trial: 1960663
Drug: Placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution placed in periodontal pockets (Control)
Trial: 6452797
Drug: Zimelidine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zimelidine 300 mg
Trial: 31851385
Drug: Tailored and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored and dose-dense (DD) epirubicin and cyclophosphamide followed by docetaxel + 1 year of adjuvant trastuzumab
Trial: 29146647
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (NOT) consisting of intravenous antibiotics for 48-72 hours, daily blood tests, and ultrasound follow-up, followed by oral antibiotics if discharge criteria are met.
Trial: 29146647
Drug: Non-operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-operative treatment (NOT)
Trial: 22003000
Drug: Trans sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trans sodium crocetinate (TSC) at doses above 1.00 mg/kg
Trial: 18069698
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for 48 weeks
Trial: 18069698
Drug: Variable treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable treatment (peginterferon alfa‐2a, 180 mg/week, or peginterferon alfa‐2b, 1.5 mg/kg/week, plus ribavirin, 1000‐1200 mg/day) for individualized duration based on HCV RNA negativity at weeks 4, 8, or 12
Trial: 18069698
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Trial: 18069698
Drug: Variable treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Variable treatment for patients who first achieved undetectable HCV RNA at weeks 4, 8, or 12
Trial: 18069698
Drug: Treatment duration
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment duration of 48 weeks versus 24 weeks for RVR patients with baseline viremia >or=400,000 IU/mL
Trial: 11948034
Drug: Megestrol acetate
RxNorm normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Megestrol acetate (MA), 800 mg/d oral suspension for 8 weeks
Trial: 9500751
Drug: Salmeterol (42
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (42 microg twice daily for 12 weeks)
Trial: 6454366
Drug: Sulfentanil (0.00015,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfentanil (0.00015, 0.0003, 0.0006 mg/kg)
Trial: 6454366
Drug: Morphine (0.100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.100, 0.150, 0.200 mg/kg)
Trial: 6454366
Drug: Fentanyl (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (not specified dosage)
Trial: 6454366
Drug: Sulfentanil, Morphine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfentanil, Morphine, Fentanyl
Trial: 27477289
Drug: Antibody-mediated blockade
RxNorm normalized name: digoxin antibodies Fab fragments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-mediated blockade of CD47 and targeting of CD271+ melanoma cells
Trial: 21878579
Drug: Celecoxib dosed
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib dosed at 3 mg/kg bid
Trial: 21878579
Drug: Celecoxib dosed
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Celecoxib dosed at 6 mg/kg bid
Trial: 21878579
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg bid capsule (or sprinkles) for patients weighing 10 to 25 kg
Trial: 21878579
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg bid for patients >25 kg
Trial: 18925413
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of salbutamol
Trial: 19146755
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug susceptibility testing (DST)
Trial: 15718314
Drug: pegfilgrastim 6
RxNorm normalized name: PEGFILGRASTIM 6MG/0.6ML DELIVERY KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pegfilgrastim 6 mg subcutaneously on day 2 of each 21-day chemotherapy cycle
Trial: 7596183
Drug: Chemotherapy protocol
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy protocol adapted from the multicentre German study
Trial: 2087879
Drug: CVD 103-HgR
RxNorm normalized name: Vibrio cholerae CVD 103-hgr strain live antigen
DrugBank: Vibrio cholerae CVD 103-HgR strain live antigen (DB14443)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CVD 103-HgR vaccine (5 x 10^8 viable organisms)
Trial: 620478
Drug: Oral chlormethiazole
RxNorm normalized name: chlormethiazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral chlormethiazole
Trial: 620478
Drug: Intravenous chlormethiazole
RxNorm normalized name: chlormethiazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous chlormethiazole
Trial: 28826192
Drug: Pridopidine 45
RxNorm normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pridopidine 45 mg twice daily (BID)
Trial: 19144760
Drug: Avosentan (5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avosentan (5, 10, 25, and 50 mg)
Trial: 14998845
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen of doxorubicin and docetaxel (60 mg/m2 each)
Trial: 14998845
Drug: Alternating regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternating regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Trial: 14998845
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen of doxorubicin and docetaxel (100 mg/m2 DOC and 75 mg/m2 doxorubicin)
Trial: 14998845
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen with prophylactic oral ciprofloxacin
Trial: 14998845
Drug: Combination regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination regimen (60 mg/m2 each)
Trial: 7862935
Drug: Fluvoxamine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 200 mg per day for 4 weeks
Trial: 7862935
Drug: Fluvoxamine 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine 200 mg per day
Trial: 2816246
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg of droperidol I.V. (n = 19)
Trial: 2816246
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg of droperidol I.V. (n = 30)
Trial: 2816246
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg of droperidol I.V. (n = 32)
Trial: 2816246
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (2 ml) (n = 49)
Trial: 824860
Drug: amilorid (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amilorid (10 mg daily, orally) for two days
Trial: 824860
Drug: potassium canrenoate
RxNorm normalized name: Potassium canrenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: potassium canrenoate (200 mg daily, i.v.) for two days
Trial: 824860
Drug: amilorid (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amilorid (10 mg daily) long-term treatment (up to 14 weeks)
Trial: 824860
Drug: spironolactone (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: spironolactone (200 mg daily) long-term treatment (up to 14 weeks)
Trial: 824860
Drug: chlortalidone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chlortalidone (50 mg daily) long-term treatment (up to 14 weeks)
Trial: 23997364
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg tiagabine
Trial: 16750452
Drug: Fenofibrate 145
RxNorm normalized name: fenofibrate 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145 mg with ezetimibe 10 mg
Trial: 16750452
Drug: Fenofibrate 145
RxNorm normalized name: fenofibrate 145 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibrate 145 mg alone
Trial: 16750452
Drug: Ezetimibe 10
RxNorm normalized name: ezetimibe 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe 10 mg alone
Trial: 14636761
Drug: Biobrane-L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biobrane-L
Trial: 1794819
Drug: Half-strength povidone-iodine
RxNorm normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half-strength povidone-iodine solution applied for 2 minutes
Trial: 6349444
Drug: Rifampicin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rifampicin (600 mg daily for 6 weeks)
Trial: 6349444
Drug: Prednisolone (increased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (increased dosage)
Trial: 24119734
Drug: Sequential interferon
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential interferon alpha‐1b (IFNa‐1b) for 6 months
Trial: 24119734
Drug: Telbivudine (LdT)
DrugBank: Telbivudine (DB01265)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telbivudine (LdT) treatment continued for an additional 6 months
Trial: 19445374
Drug: Intrauterine fetoscopic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrauterine fetoscopic surgical treatment using a 2-mm endoscope and diode laser fiber, performed under local anesthesia, through a single 3-mm trocard.
Trial: 14649785
Drug: Guided self-change
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guided self-change (self-care manual plus eight fortnightly sessions of cognitive behavioural therapy)
Trial: 14649785
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy (16 weekly sessions)
Trial: 8999458
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) administered intravenously at a dose of 50 U/kg body mass
Trial: 8434742
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of fentanyl at a rate of 50 micrograms.h‐1 with additional epidural boluses (25 micrograms) as required
Trial: 8434742
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of patient-controlled analgesia and continuous infusion
Trial: 8434742
Drug: Nurse-administered analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurse-administered analgesia (implied control)
Trial: 2957210
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg CM 57755
Trial: 2957210
Drug: 0.5 g
RxNorm normalized name: Gelatin Capsules, 10.5 gr
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 g CM 57755
Trial: 2957210
Drug: 1.0 g
RxNorm normalized name: IODINE 11.0 g in 1 L TOPICAL SOLUTION [T.D.]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 g CM 57755
Trial: 26211531
Drug: Resistance training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance training based physical activity program with weekly discussions on health and quality of life (Mental group)
Trial: 20378585
Drug: 16 mg
RxNorm normalized name: escin 16 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 mg ENDD
Trial: 20378585
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg ENDD (placebo)
Trial: 8784084
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methimazole daily plus sufficient T4 to maintain TSH in the high-normal range (Group 2)
Trial: 8784084
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg methimazole daily plus sufficient T4 to suppress TSH to below 0.6 mIU/L (Group 3)
Trial: 1473391
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 mg/kg i.v. under normal condition (PetCO2 5‐5.5kPa)
Trial: 1473391
Drug: Succinylcholine 1
RxNorm normalized name: Succinylcholine 124 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Succinylcholine 1 mg/kg i.v. under hyperventilation (PetCO2 3‐3.5kPa)
Trial: 6734304
Drug: Rectal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal administration of bacampicillin hydrochloride (400 mg)
Trial: 6734304
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of bacampicillin hydrochloride (400 mg)
Trial: 30609152
Drug: Risperidone (continued
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (continued treatment group)
Trial: 31109200
Drug: Placebo (discontinuation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (discontinuation group)
Trial: 26897490
Drug: Liposomal bupivacaine
RxNorm normalized name: bupivacaine liposome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liposomal bupivacaine (LB) periarticular injection, n = 20
Trial: 26897490
Drug: Standard periarticular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard periarticular injection (ropivacaine, clonidine, Toradol, Epinepherine, saline), n = 18
Trial: 20574936
Drug: Hypnoreflexogenous birth
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnoreflexogenous birth preparation course